Attovia Therapeutics (ATTO) KOL event & Study update summary

ATTO-1310 profile

• Anti-IL-31 ligand ATTOBODY-based fusion biologic with YTE Fc, designed for rapid itch relief and quarterly subcutaneous maintenance dosing.

Study design and pharmacology

• Phase 1b randomized, double-blind, placebo-controlled study assessed one SC dose of ATTO-1310 (4.5 or 9 mg/kg) in chronic pruritus and high-itch AD cohorts; rescue therapy was allowed after Week 4.

• Drug concentrations remained above in-vitro IC90, with ~95% suppression of free IL-31 through Week 12 after one dose, supporting potential quarterly maintenance dosing.

KOL perspectives and unmet need

• CPUO affects an estimated 2–5M US adults; reported burden included median worst itch of 7.5/10, itch lasting >1 year in 78%, and daily itch in 68%; no FDA-approved treatments.

• Severe itch-dominant AD with mild-to-moderate lesions may affect 25%–33% of adults with AD; no systemic therapy is approved, and lesion-based thresholds may underestimate disease burden.